Specifically, we posit that reduction of Oscillibacter (and potentially other bacterial producers of Tlr2/5 ligands) levels and the consequent decrease and/or reprogramming of metabolically harmful IR-ATMs represents one of the main mechanisms of TXN therapeutic action in MetS (Fig. 6). The gene discussed is TXN; the disease is metabolic syndrome.